

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

#110
PATENT
9-28-01
Attorney Docket No.: 15270J-004750US
Client Ref. No. 209-US-CIP8A

O I P E Assistant Commissioner for Patents

Box SEQUENCE
Washington, D.C. 20231

SEP 19 2001

On September 11, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Wanda Alleje
Wanda Alleje

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schenk et al.

Application No.: 09/580,015

Filed: May 26, 2000

For: PREVENTION AND
TREATMENT OF
AMYLOIDOGENIC DISEASE

Examiner: UNASSIGNED

Art Unit: 1641

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith the required paper and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

The paragraph beginning at page 7, line 32, has been amended as follows:

Fig. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number F10920M shows a representative N-terminal restricted response to the peptide